Analysts/Institutional Investor Meet/Con. Call Updates

AI summary - Q1 FY27 consolidated revenue INR56.9 Cr, +22% y-y; EBITDA INR8.3 Cr, +27% y-y; PAT INR4 Cr, +25% y-y - EBITDA margin improved to 14.6% vs 14.1% in Q1 FY26 and 13.3% in Q4 FY26 - Q1 revenue up 28% q-q; EBITDA +41% q-q; PAT more than doubled q-q - PSP revenue INR17.6 Cr; B2B health camps revenue INR6.4 Cr with 11,497 camps in Q1 - Saarathi Healthcare 76% owned; full acquisition expected by Q2 FY27 - Q Devices revenue INR3 Cr in Q1; targeting 10-15% contribution in FY27 and 20-25% of product revenue in 3 years - FY27 service revenue guidance INR90-100 Cr; total revenue guidance ~INR220 Cr maintained - Employee expenses increased due to PSP hiring; expected stable run rate with possible increases on new contracts - Gross margin expansion driven by higher services revenue share (40% in Q1 vs 30% last year) - Contract renewals at 60-70%; price hikes of 5-12% annually in PSP agreements - PSP programs include patented and generic molecules, focus on chronic and specialty therapies - Management confident on sustainable growth and integration of Saarathi strengthening patient support capabilities